StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals Annual Incentive Program Corporate Performance Modifier by Year

Annual Incentive Program (AIP) Corporate Performance Modifier (% of Target Payout) (%)

Alnylam Pharmaceuticals Annual Incentive Program Corporate Performance Modifier: 200.0% in FY2025, up 10.0 pts from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
200.0%
Period ended Dec 31, 2025
Change on a year earlier
+10.0 pts
190.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“recommended, and the board approved, a corporate performance modifier of 200%”

Source: Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗

Reported in DEF 14A Definitive Proxy Statements (Executive Compensation, CEO Pay Ratio & Pay Versus Performance).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up annual Incentive Program Corporate Performance Modifier

Cite this data

StockData. (2026). Alnylam Pharmaceuticals Annual Incentive Program Corporate Performance Modifier (%), annual FY2018–FY2025 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/proxy-aip-modifier

See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?